Project Grant R01HL177355
Award Date
12/26/24
Completion Date
11/30/29
Dollars Obligated
$786K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel hydrogel-based system for delivering gene therapy to the heart. The primary awardee, Emory University, will engineer a hydrolysis-cleavable polyethylene glycol (PEG) hydrogel to target the epicardium and optimize cardiac transduction of gene therapy vectors. The total funding amount is $635,300.00, with a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This $560,000 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), aims to develop a novel triple gene therapy approach to treat ischemic heart failure. The research team at Baylor College of Medicine, the prime awardee, will conduct preclinical testing to determine the optimal dosage and evaluate the efficacy and initial safety of this triple therapy in animal models and human heart slices....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,654,903 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop innovative gene therapy technologies for the in vivo and ex vivo delivery of genetic payloads to hematopoietic stem cells. The objectives are to: (1) develop integrating vectors to deliver a curative transgene for X-linked...
This $817,208 Project Grant was awarded on January 3, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research at the Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project will leverage high-throughput assays, including cell painting and Perturb-seq, to link genes associated with HF risk through genome-wide association...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award for $300,000, with a performance period from September 10, 2024 to September 9, 2025, supports research by Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease using a novel lentiviral vector technology. The project aims to assess the efficiency and specificity of the company's "GigaLenti" lentiviral vector platform in delivering CRISPR/Cas9 gene editing machinery to knockout the BCL11A...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $317,285 to Rithim Biologics Inc. to develop a novel gene therapy approach to prevent ventricular tachycardia (VT) following myocardial infarction. The project aims to finalize the development of an epicardial gene painting catheter, verify ventricular-targeted transgene expression, and evaluate biodistribution and toxicity in an...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,665 to the New York Genome Center, Inc. (Nygc) to develop scalable methods for identifying causal genetic variants, relevant cell types, and target genes associated with cardiovascular disease (CVD). The key products and services to be delivered include: Performing colocalization of CVD and blood cell trait genome-wide association...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $814,209 to the Fred Hutchinson Cancer Center in Seattle, Washington to develop CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy. The goal is to enable safe and efficient genetic modification of blood stem cells directly in patients, overcoming limitations of current ex vivo gene therapy approaches. The project...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $647,359 to Oregon Health & Science University (OHSU) to develop novel biomaterials and gene delivery technologies to improve cardiovascular treatments. The key objectives are to: (1) create non-viral delivery of miRNA-145 using OHSU's PVA-CDI immobilized aminated fucoidan (PCAF) biomaterials for sustained release, (2)...